Topics

Clinical Trials About "EyePoint Pharmaceuticals Announces Agreement Expanded Access DEXYCU Within" RSS

20:56 EST 27th January 2020 | BioPortfolio

We list hundreds of Clinical Trials about "EyePoint Pharmaceuticals Announces Agreement Expanded Access DEXYCU Within" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "EyePoint Pharmaceuticals Announces Agreement Expanded Access DEXYCU Within" on BioPortfolio

We have published hundreds of EyePoint Pharmaceuticals Announces Agreement Expanded Access DEXYCU Within news stories on BioPortfolio along with dozens of EyePoint Pharmaceuticals Announces Agreement Expanded Access DEXYCU Within Clinical Trials and PubMed Articles about EyePoint Pharmaceuticals Announces Agreement Expanded Access DEXYCU Within for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of EyePoint Pharmaceuticals Announces Agreement Expanded Access DEXYCU Within Companies in our database. You can also find out about relevant EyePoint Pharmaceuticals Announces Agreement Expanded Access DEXYCU Within Drugs and Medications on this site too.

Showing "EyePoint Pharmaceuticals Announces Agreement Expanded Access DEXYCU Within" Clinical Trials 1–25 of 3,900+

Extremely Relevant

Expanded Access to Omaveloxolone for Melanoma for Patients Previously Enrolled in 408-C-1401

This is an expanded access program for eligible participants and is designed to provide access to omaveloxolone for the treatment of unresectable or metastatic melanoma to patients who previously participated in the 408-C-1401 (REVEAL) study. To be considered for expanded access, a Principal Investigator from the REVEAL trial should submit a request to Reata Pharmaceuticals on behalf of the individual patient.


Relevant

Expanded Access for AG-221

This is an expanded access program (EAP) for eligible participants designed to provide access to AG-221.

Expanded Access for CC-486

This is an expanded access program (EAP) for eligible participants designed to provide access to CC-486.


Expanded Access for ACE-011

This is an expanded access program (EAP) for eligible participants designed to provide access to ACE-011.

AMG 714 Expanded Access Program

Expanded access requests for AMG 714 may be considered for adult patients with biopsy proven Refractory Celiac Disease Type II who have failed all available treatment options and do not have EATL. To request access, use Responsible Party contact information provided in this record.

Expanded Access of Vigil in Solid Tumors

This is a multicenter, expanded access protocol of intradermal autologous Vigil immunotherapy. Subjects meeting expanded access eligibility criteria will receive a minimum of 1 immunotherapy dose of Vigil (1 x 10e4, 1 x 10e5, or 1 x 10e6 cells/injection), intradermally every 4 weeks as monotherapy.

Intermediate Expanded Access Protocol for ALS

This is a single-center intermediate expanded access program to provide access to the investigational product, CNM-Au8, up to twenty participants diagnosed with ALS who are otherwise ineligible for participation in clinical studies with CNM-Au8.

Individual Patient Expanded Access for AB-SA01, an Investigational Anti-Staphylococcus Aureus Bacteriophage Therapeutic

The purpose of the expanded access program is to allow physicians to provide treatment with investigational drug, AB-SA01, for patients with serious or immediately life-threatening Staphylococcus aureus infections, for which no alternative treatment(s) are currently available, and who meet the criteria for treatment under FDA's Expanded Access regulations and criteria set forth by AmpliPhi Biosciences Corporation. To be considered for expanded access, the request should be sub...

Individual Patient Expanded Access for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage Therapeutic

The purpose of the expanded access program is to allow physicians to provide treatment with investigational drug, AB-PA01, for patients with serious or immediately life-threatening Pseudomonas aeruginosa infections, for which no alternative treatment(s) are currently available, and who meet the criteria for treatment under FDA's Expanded Access regulations and criteria set forth by AmpliPhi Biosciences Corporation. To be considered for expanded access, the request should be su...

Individual Patient Expanded Access Gilteritinib (ASP2215)

The purpose of this study is to provide expanded access to ASP2215 for a single subject with refractory FLT3-mutated AML without access to comparable or alternative therapy.

Expanded Access for Fedratinib

This is an expanded access program (EAP) for eligible participants designed to provide access to Fedratinib.

Expanded Access for CC-4047

This is an expanded access program (EAP) for eligible participants designed to provide access to CC-4047.

Expanded Access for CC-10004

This is an expanded access program (EAP) for eligible participants designed to provide access to CC-10004.

Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to SUVN-502 for the treatment of Alzheimer's Disease. Investigator as well as the subject/caregiver must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the patient's medical history and program eligibility criteria. Subjects will not be evaluated for efficacy and safety during the expanded access.

Expanded Access for CC-2001

This is an expanded access program (EAP) for eligible participants designed to provide access to CC-2001.

Expanded Access to Provide LOXO-195 for the Treatment of Cancers With a NTRK Gene Fusion

LOXO-195 expanded access is for patients with cancer with a NTRK1, NTRK2, or NTRK3 gene fusion who are ineligible for an ongoing LOXO-195 clinical trial or have other considerations that prevent access to LOXO-195 through an existing clinical trial. Expanded access is intended to treat individual patients with different types of cancers, including blood cancers, with a NTRK gene fusion who have previously received TRK inhbitor therapy

Expanded Access for Treatment Use of PLX-PAD in Critical Limb Ischemia (CLI)

This is an Expanded Access program (EAP), sponsored by WideTrial for the treatment of critical limb ischemia (CLI). Widetrial, an Expanded Access specialist, has arranged to supply participating sites with PLX-PAD for CLI patients who cannot participate in the ongoing research trial and who seek exploratory treatment options. This program includes FDA-authorized cost recovery, meaning payment is required to cover a portion of the costs of delivering product and complying with ...

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Expanded access for patients with cancer with RET activation who are ineligible for an ongoing LOXO-292 clinical trial or have other considerations that prevent access to LOXO-292 through an existing clinical trial.

Expanded Access for ATB200/AT2221 for the Treatment of LOPD

This is an expanded access program (EAP) for eligible participants designed to provide access to ATB200/AT2221.

Expanded Access Protocol of ZULRESSO™ (Brexanolone) Injection for Adult Patients With Postpartum Depression

This is an expanded access program intended to provide access to ZULRESSO™ (brexanolone) injection for the treatment of a limited number of eligible women with postpartum depression during the period prior to commercial availability. Requests for access must be made by a healthcare provider for a specific patient based on a determination with patient that the benefits of treatment outweigh the risks and an assessment of eligibility based on program criteria. Sites with eligib...

Expanded Access to NanoPac

NanOlogy may consider offering expanded access to NanoPac for patients who do not meet the enrollment criteria of clinical trials in progress.

Expanded Access to NanoDoce

NanOlogy may consider offering expanded access to NanoDoce for patients who do not meet the enrollment criteria of clinical trials in progress.

Expanded Access to Provide Larotrectinib (LOXO-101) for the Treatment of Cancers With a NTRK Gene Fusion

Larotrectinib (LOXO-101) expanded access is for patients with cancer with a NTRK1, NTRK2, or NTRK3 gene fusion who are ineligible for an ongoing larotrectinib (LOXO-101) clinical trial or have other considerations that prevent access to larotrectinib (LOXO-101) through an existing clinical trial. Expanded access is intended to treat individual patients with different types of cancers with a NTRK gene fusion.

Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy

An expanded access/compassionate use protocol that allows access to Mylotarg for relapsed/refractory AML CD33 positive patients in the USA. Contact: B1761026@iconplc.com

Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care

GL-ONC1 expanded access is for patients who are ineligible for an ongoing GL-ONC1 clinical trial. Expanded access is intended to treat individual patients with advanced stage cancers, including blood cancer, with no standard of care options for treatment. Potential patients will be evaluated individually depending on GL-ONC1 product supply.


More From BioPortfolio on "EyePoint Pharmaceuticals Announces Agreement Expanded Access DEXYCU Within"

Quick Search